[go: up one dir, main page]

MX2023001193A - Composicion de un anticuerpo inhibidor de masp-2 para usarse en el tratamiento de un padecimiento asociado con la activacion del complemento dependiente de masp-2. - Google Patents

Composicion de un anticuerpo inhibidor de masp-2 para usarse en el tratamiento de un padecimiento asociado con la activacion del complemento dependiente de masp-2.

Info

Publication number
MX2023001193A
MX2023001193A MX2023001193A MX2023001193A MX2023001193A MX 2023001193 A MX2023001193 A MX 2023001193A MX 2023001193 A MX2023001193 A MX 2023001193A MX 2023001193 A MX2023001193 A MX 2023001193A MX 2023001193 A MX2023001193 A MX 2023001193A
Authority
MX
Mexico
Prior art keywords
masp
dependent complement
activation
treatment
composition
Prior art date
Application number
MX2023001193A
Other languages
English (en)
Inventor
Thomas Dudler
Hans- Wilhelm Schwaeble
Demopulos Gregory A
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of MX2023001193A publication Critical patent/MX2023001193A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Power Steering Mechanism (AREA)
  • Exhaust Gas After Treatment (AREA)

Abstract

En un aspecto, la invención proporciona métodos para la inhibición de los efectos de la activación del complemento dependiente de MASP-2 en un sujeto humano que padece TMA asociada con trasplante de células madre hematopoyéticas. Los métodos comprenden la etapa de administrar, a un sujeto que lo necesite, una cantidad de un agente inhibidor de MASP-2 efectiva para inhibir la activación del complemento dependiente de MASP-2.
MX2023001193A 2015-11-09 2018-04-25 Composicion de un anticuerpo inhibidor de masp-2 para usarse en el tratamiento de un padecimiento asociado con la activacion del complemento dependiente de masp-2. MX2023001193A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562252814P 2015-11-09 2015-11-09
US201662406726P 2016-10-11 2016-10-11

Publications (1)

Publication Number Publication Date
MX2023001193A true MX2023001193A (es) 2023-08-11

Family

ID=58691444

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018005165A MX2018005165A (es) 2015-11-09 2016-11-09 Métodos para el tratamiento de padecimientos asociados con la activacion del complemento dependiente de masp-2.
MX2023001193A MX2023001193A (es) 2015-11-09 2018-04-25 Composicion de un anticuerpo inhibidor de masp-2 para usarse en el tratamiento de un padecimiento asociado con la activacion del complemento dependiente de masp-2.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018005165A MX2018005165A (es) 2015-11-09 2016-11-09 Métodos para el tratamiento de padecimientos asociados con la activacion del complemento dependiente de masp-2.

Country Status (19)

Country Link
US (3) US20170137537A1 (es)
EP (1) EP3373963A4 (es)
JP (2) JP6814802B2 (es)
KR (2) KR102277166B1 (es)
CN (2) CN117398458A (es)
AU (2) AU2016354117B2 (es)
CA (1) CA3004753C (es)
CL (1) CL2018001258A1 (es)
EA (1) EA201891132A1 (es)
GE (2) GEP20247583B (es)
IL (2) IL259225B (es)
MD (1) MD4685C1 (es)
MX (2) MX2018005165A (es)
MY (1) MY197758A (es)
NZ (1) NZ742987A (es)
PH (1) PH12018501009A1 (es)
SG (2) SG11201803834UA (es)
UA (1) UA124094C2 (es)
WO (1) WO2017083371A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101870915B1 (ko) 2011-04-08 2018-06-25 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
NZ719476A (en) 2013-10-17 2022-07-29 Omeros Corp Methods for treating conditions associated with masp-2 dependent complement activation
AU2017293767B2 (en) * 2016-07-06 2021-12-16 Microoptx Inc. Glaucoma treatment devices and methods
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
TW202529812A (zh) * 2017-08-15 2025-08-01 美商歐米諾斯公司 用於治療和／或預防與造血幹細胞移植有關的移植物抗宿主病和／或瀰漫性肺泡出血和／或靜脈閉塞性病的方法
IL272673B2 (en) * 2017-08-25 2024-10-01 Omeros Corp Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and use for treating subjects suffering from atypical hemolytic syndrome
JP7536655B2 (ja) 2018-05-29 2024-08-20 オメロス コーポレーション Ｍａｓｐ－２阻害剤および使用方法
WO2019246367A1 (en) * 2018-06-22 2019-12-26 Omeros Corporation Compositions and methods of inhibiting masp-2 for the treatment of various thrombotic diseases and disorders
MX2022006334A (es) * 2019-11-26 2022-06-22 Omeros Corp Metodos para tratar y/o prevenir el sindrome de neumonia idiopatica (ips) y/o el sindrome de fuga capilar (cls) y/o el sindrome de injerto (es) y/o la sobrecarga de fluidos (fo) asociados con el trasplante de celulas madre hematopoyeticas.
US11661418B2 (en) 2019-12-04 2023-05-30 Omeros Corporation MASP-2 inhibitors and methods of use
WO2021113698A1 (en) 2019-12-04 2021-06-10 Omeros Corporation Masp-2 inhibitors and methods of use
BR112022010890A2 (pt) 2019-12-04 2022-08-16 Omeros Corp Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado a serina protease-2 associada à lectina de ligação ao manan
IL293550A (en) 2019-12-04 2022-08-01 Omeros Corp 2-masp inhibitor compounds, preparations containing them and their uses
WO2022006470A1 (en) 2020-07-01 2022-01-06 Vanderbilt University Methods of treatment for a kidney disease
TWI892695B (zh) 2021-12-10 2025-08-01 美商歐米諾斯公司 結合ｍａｓｐ－２的絲氨酸蛋白酶結構域的治療性抗體及其用途
EP4626891A1 (en) 2022-11-30 2025-10-08 Omeros Corporation Fused pyrimidines as masp-2 inhibitors
US20250122225A1 (en) 2023-10-06 2025-04-17 Omeros Corporation Masp-2 inhibitors and methods of use
WO2025153000A1 (zh) * 2024-01-17 2025-07-24 信立泰(成都)生物技术有限公司 一种抗masp2抗体或其抗原结合片段及用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4394370A (en) 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4526909A (en) 1984-01-09 1985-07-02 Regents Of The University Of California Polymethylmethacrylate delivery system for bone morphogenetic protein
US4563489A (en) 1984-02-10 1986-01-07 University Of California Biodegradable organic polymer delivery system for bone morphogenetic protein
JPH0662679B2 (ja) 1985-06-21 1994-08-17 新田ゼラチン株式会社 組織親和性コラ−ゲンとその製法
US5453566A (en) 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
EP0640688A1 (en) 1987-12-15 1995-03-01 Gene Shears Pty. Limited Ribozymes
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8822492D0 (en) 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
ATE149841T1 (de) 1990-01-26 1997-03-15 Immunomedics Inc Impfstoffe gegen krebs und infektionskrankheiten
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
AU4467396A (en) 1994-12-12 1996-07-10 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
EP2322226A3 (en) 1999-07-21 2011-08-17 Omeros Corporation Solutions and methods for inhibition of pain, inflammation and cartilage degradation
EP1204419A1 (en) * 1999-08-13 2002-05-15 The Brigham And Women's Hospital, Inc. Inhibitors of the lectin complement pathway (lcp) and their use
US6649592B1 (en) 2000-01-14 2003-11-18 Science & Technology Corporation @ Unm Peptide inhibitors of LFA-1/ICAM-1 interaction
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
MXPA04007124A (es) 2002-02-01 2004-10-29 Omeros Corp Composiciones y metodos para la inhibicion sistemica de la degradacion del cartilago.
AU2003249317B2 (en) 2002-07-19 2007-08-02 Institute Of Materials Research And Engineering Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
US20130266559A1 (en) 2004-06-10 2013-10-10 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20150166676A1 (en) * 2011-04-08 2015-06-18 Omeros Corporation Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
KR101870915B1 (ko) * 2011-04-08 2018-06-25 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
EP3725811A3 (en) 2011-05-04 2021-01-27 Omeros Corporation Compositions for inhibiting masp-2 dependent complement activation
KR102339315B1 (ko) * 2012-06-18 2021-12-15 오메로스 코포레이션 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법
EP3722320A3 (en) 2012-10-25 2020-12-30 Bioverativ USA Inc. Anti-complement c1s antibodies and uses thereof
US10815296B2 (en) * 2013-09-16 2020-10-27 Children's Hospital Medical Center Methods of treatment of HSCT-associated thrombotic microangiopathy with eculizumab
NZ719476A (en) * 2013-10-17 2022-07-29 Omeros Corp Methods for treating conditions associated with masp-2 dependent complement activation
KR102011118B1 (ko) * 2018-04-13 2019-08-14 김정범 개선된 스냅 단추

Also Published As

Publication number Publication date
CA3004753C (en) 2023-02-28
CN108472347A (zh) 2018-08-31
JP6814802B2 (ja) 2021-01-20
US20240343830A1 (en) 2024-10-17
IL259225A (en) 2018-07-31
NZ742987A (en) 2019-12-20
KR102277166B1 (ko) 2021-07-15
BR112018009311A2 (pt) 2018-11-06
KR20210090283A (ko) 2021-07-19
CL2018001258A1 (es) 2018-10-12
US11981749B2 (en) 2024-05-14
IL259225B (en) 2022-09-01
IL295200B2 (en) 2025-04-01
EP3373963A1 (en) 2018-09-19
SG10202011469UA (en) 2020-12-30
MD4685C1 (ro) 2020-12-31
IL295200B1 (en) 2024-12-01
AU2016354117B2 (en) 2019-11-28
SG11201803834UA (en) 2018-06-28
EA201891132A1 (ru) 2018-10-31
MD4685B1 (ro) 2020-03-31
KR20180074789A (ko) 2018-07-03
BR112018009311A8 (pt) 2019-02-26
CA3004753A1 (en) 2017-05-18
GEP20237574B (en) 2023-12-25
KR102432062B1 (ko) 2022-08-12
CN117398458A (zh) 2024-01-16
MY197758A (en) 2023-07-13
UA124094C2 (uk) 2021-07-21
IL295200A (en) 2022-10-01
PH12018501009A1 (en) 2019-01-28
MX2018005165A (es) 2020-11-11
JP2018533592A (ja) 2018-11-15
AU2020201500A1 (en) 2020-03-19
MD20180042A2 (ro) 2018-09-30
EP3373963A4 (en) 2019-07-10
AU2016354117A1 (en) 2018-05-10
CN108472347B (zh) 2023-09-05
US20170137537A1 (en) 2017-05-18
JP7629300B2 (ja) 2025-02-13
US20210047433A1 (en) 2021-02-18
WO2017083371A1 (en) 2017-05-18
JP2021063093A (ja) 2021-04-22
GEP20247583B (en) 2024-01-10

Similar Documents

Publication Publication Date Title
MX2023001193A (es) Composicion de un anticuerpo inhibidor de masp-2 para usarse en el tratamiento de un padecimiento asociado con la activacion del complemento dependiente de masp-2.
ZA202407503B (en) Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant
MX2021008044A (es) Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2.
EA201890161A1 (ru) Терапевтические композиции, комбинации и способы применения
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890047A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890048A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891202A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890051A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890049A1 (ru) Композиции, содержащие бактериальные штаммы
MX2017016517A (es) Composiciones estables al almacenamiento y metodos para el tratamiento de errores de refraccion del ojo.
EA201790170A1 (ru) Терапевтические соединения-ингибиторы
MX2016011072A (es) Derivado de pirazol amida.
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
ECSP14030779A (es) Inhibidores del nampt
MX2017002382A (es) Metodos para tratar el mieloma multiple con compuestos imunomodulares en combinacion con anticuerpos.
MX381544B (es) Composición de células estromales mesenquimatosas para usare en el tratamiento de la sepsis en un sujeto.
MX388559B (es) Anticuerpo monoclonal humanizado para inhibir la actividad enzimatica de la lipasa endotelial vascular.
MX2017007000A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
MX2014008336A (es) Combinacion farmacologica antihiperalgesica, antialodinica y antiinflamatoria, composiciones farmaceuticas que la contienen, y su uso para el tratamiento del dolor neuropatico.
MX2017014128A (es) 2-tiopirimidinonas.
EA201791483A1 (ru) Фармацевтическая композиция для лечения микоза